EXAPRIDE

Main information

  • Trade name:
  • EXAPRIDE 1 INJ
  • Dosage:
  • 250MCG/ML
  • Pharmaceutical form:
  • INJ
  • Composition:
  • 1
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EXAPRIDE 1 INJ
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

13-10-2017

Pending EC decision:  Bydureon, exenatide, Opinion date: 12-Oct-2017

Pending EC decision: Bydureon, exenatide, Opinion date: 12-Oct-2017

Europe - EMA - European Medicines Agency

21-7-2017

Pending EC decision:  Bydureon, exenatide, Opinion date: 20-Jul-2017

Pending EC decision: Bydureon, exenatide, Opinion date: 20-Jul-2017

Europe - EMA - European Medicines Agency

23-3-2018

BYETTA (Exenatide) Injection [AstraZeneca Pharmaceuticals LP]

BYETTA (Exenatide) Injection [AstraZeneca Pharmaceuticals LP]

Updated Date: Mar 23, 2018 EST

US - DailyMed

28-8-2017

BYDUREON (AstraZeneca AB)

BYDUREON (AstraZeneca AB)

BYDUREON (Active substance: exenatide) - Centralised - 2-Monthly update - Commission Decision (2017)5937 of Mon, 28 Aug 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/2020/II/41

Europe -DG Health and Food Safety